Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 4/20 | 0.55 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.48 |
| ▸ | VNN1 | O95497 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.34 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18125968 | 0.82 | PDK1 (0.56) | PDK1GLRA1VNN1ALDH1A1NPC1 | |
| SCHEMBL2933380 | 0.82 | PDK1 (0.56) | PDK1GLRA1VNN1ALDH1A1NPC1 | |
| SCHEMBL15788160 | 0.82 | PDK1 (0.56) | PDK1GLRA1VNN1ALDH1A1NPC1 | |
| SCHEMBL3991342 | 0.82 | PDK1 (0.56) | PDK1GLRA1VNN1ALDH1A1NPC1 | |
| SCHEMBL17776430 | 0.82 | PDK1 (0.56) | PDK1GLRA1VNN1ALDH1A1NPC1 | |
| SCHEMBL18125963 | 0.82 | PDK1 (0.56) | PDK1GLRA1VNN1ALDH1A1NPC1 | |
| SCHEMBL24318910 | 0.80 | PDK1 (0.55) | PDK1GLRA1VNN1PIK3CDPIK3R2 | |
| SCHEMBL6223992 | 0.80 | PDK1 (0.55) | PDK1GLRA1VNN1PIK3CALMNA | |
| SCHEMBL3805230 | 0.80 | PDK1 (0.65) | PDK1GLRA1VNN1ALDH1A1 | |
| SCHEMBL21884847 | 0.80 | PDK1 (0.55) | PDK1GLRA1VNN1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-115551487-A | Methods and compositions for treating anemia using ACTRIIB ligand traps and mTOR inhibitors | 细胞基因公司 | 2022-12-30 | — | — | CN | disclosed |
| US-11325940-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3292117-B1 | PYRIDAZINE DERIVATIVES AS RORC MODULATORS | HOFFMANN LA ROCHE (CH) | 2020-08-12 | — | — | EP | disclosed |
| WO-2020135210-A1 | SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2020-07-02 | — | — | WO | disclosed |
| WO-2020099511-A1 | BENZIMIDAZOLE-2-METHYL-MORPHOLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-05-22 | — | — | WO | disclosed |
| CN-107406452-B | Pyrazolo [3,4-d] pyrimidine derivatives and its purposes for treating leishmaniasis | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-07-23 | — | — | CN | disclosed |
| US-10105426-B2 | Immunostimulatory combinations | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2018-10-23 | — | — | US | disclosed |
| CN-107311961-A | A kind of reduction COMU synthesis technique | 成都巴赛泰德生物科技有限公司 | 2017-11-03 | — | — | CN | disclosed |
| US-20160129095-A1 | Immunostimulatory Combinations | DARTMOUTH COLLEGE (US) | 2016-05-12 | — | — | US | disclosed |
| US-20130115228-A1 | IMMUNOSTIMULATORY COMBINATIONS | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-8329197-B2 | Ex vivo uses of immunostimulatory combinations | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-20110280903-A1 | IMMUNOSTIMULATORY COMBINATIONS | NOELLE RANDOLPH J (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-7993659-B2 | TLR9 agonist and CD40 agonist immunostimulatory combinations | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110002946-A1 | Immunostimulatory Combinations | NOELLE RANDOLPH J | 2011-01-06 | — | — | US | disclosed |
| US-20090123460-A1 | IMMUNOSTIMULATORY COMBINATIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-05-14 | — | — | US | disclosed |
| US-7387271-B2 | Immunostimulatory combinations | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| US-20050158325-A1 | Immunomodulatory combinations | 3M INNOVATIVE PROPERTIES COMPANY | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325940-B2 | Certain chemical entities, compositions, and methods | TP53, VHL, SGMS2 | PDK1 1067/4885GLRA1 4820/4885VNN1 1100/4885 |
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, CLN6 | PDK1 1550/4885GLRA1 2512/4885VNN1 1895/4885 |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | CLN6, NLN, ACHE | PDK1 1982/4885GLRA1 3846/4885VNN1 1159/4885 |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | PDK1 136/4885GLRA1 3151/4885VNN1 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.